Primary Investigators: William Hawkins, MD, FACS
Pathology of human PDACInvestigators in Project 2 of the Pancreas SPORE at Washington University hope to develop a drug for the treatment of pancreatic cancer to improve survival rates. In this research, our team will work towards developing a delivery platform for small-molecule drugs that sends a drug directly to tumors and avoids adverse side effects for patients. Through clinical trials, we will be able to test the success rates of such a drug specific to pancreatic cancer. Our project has tremendous potential to overcome drug resistance, improve success rates for patients, and minimize toxicity in patients.
Overview of Project 2 in the Pancreas SPORE